4 results
•To compare progression-free survival (PFS) as assessed by blinded independent central review (BICR) between sacituzumab govitecan (SG) versus treatment of physician*s choice (TPC)Secondary Objectives:•To compare overall survival (OS) between the 2…
The primary objective of this PMCF study is to confirm device survivorship of the GLOBAL ICON stemless humeral component at 24 months post-operative.The secondary objectives include the evaluation of clinical performance, radiographic performance…
To compare the overall survival (OS) of sacituzumab govitecan (SG) versus docetaxel.
Primary objective:To assess the (short-term) safety of the WEAKID nighttime system in a limited number (n=12) of patients and sessions (6 sessions per patient).Secondary objectives1. To evaluate the incidence of AE*s and DD*s other than SADE*s and…